Navigate End-To-End Strategic Updates in NASH & Obesity to Define the Evolving Competitive Landscape in Metabolic Disorders

November 27-29 | Boston, MA

Welcome to the 7th Obesity & NASH Drug Development Summit

Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.

In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.

Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is your exclusive industry meeting to:

  • better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
  • explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
  • ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action

Join 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH.

Our Expert Speaker Faculty:

Erik Tillman

Associate Director - Translational Biology & Pharmacology

Akero Therapeutics

Jingye Zhou

Co-Founder & Chief Executive Officer


Kevin Hart

Associate Director & Fellow - Scientific, Research


Mark Hartman

Vice President, Medical, NASH/Obesity

Eli Lilly & Co.

Mary Haas

Senior Manager, Cardiovascular Metabolic & Skeletal Disease Genetics

Regeneron Pharmaceuticals Inc

Noah Davidsohn

Chief Scientific Officer

Rejuvenate Bio

Rebecca Taub

Founder, Chief Executive & Medical Officer, President - Research & Development

Madrigal Pharmaceuticals

Zhao (Joe) Wang

Regulatory Affairs Director, Late CVRM


Present a Poster

Do you have cutting-edge research that you want to share with drug developers, academics and clinicians? Submit a poster today!

Who's In The Room

34076 Who's Attending (800 x 200 px) (500 x 100 px) (3)

What do GLP-1 agonists mean for obesity and NASH treatment?

Tien Lee, CEO of Aardvark Therapeutics shares their insights.


Why is the Industry Excited to Attend:

“Quality of the speakers and the subject matter was outstanding. The attendees were very interactive and discussions in the meeting and during the breaks were excellent”

Cyta Therapeutics

“Presentations were very informative, cutting edge and "timely", representing the current state of R&D in the Obesity and NASH field, with excellent Q&A”


“Fantastic speakers and audience participation”

Myovant Sciences

“Looking forward to sharing our work and areas of interest with academic and industry colleagues to collectively discuss, identify, and solve major problems in the field to bring cutting edge treatments to patients” 


“I appreciate the focus on drug development with active participation of industry experts. With this focus, the learning is different from what one gets at meetings run by scientific societies and offers great networking opportunities” 

Eli Lilly

Proud To Partner With:

antaros logo
repair biotech
nordic bioscience
Screenshot 2023-10-26 123334
AGA Horizontal Logo - Color
logo echosens and claim_gradient (1)

Other Events In The Series Include: